Pretreatment colostomy in patients with anal squamous cell carcinoma: Risk factors for a permanent stoma
- 31 May 2022
- journal article
- research article
- Published by Wiley in Journal of Surgical Oncology
- Vol. 126 (4) , 740-747
Abstract
Background: The current standard of care for anal squamous cell carcinoma (SCC) is concurrent chemoradiation (CRT), which enables tumor eradication while preserving the anal sphincter. Patients with locally advanced tumors, however, may experience complications that preclude treatment before stoma creation.Objective: To evaluate the reversal rate of pretreatment stomas and the risk factors associated with nonreversal.Methods: This single‐institution retrospective cohort study using a prospective database included patients diagnosed with anal SCC from January 2008 to December 2020 who required a stoma before curative CRT.Results: In total, 651 patients were identified; 65 required a stoma before chemoradiation due to obstruction (43.1%), rectovaginal fistula (20%), and perianal sepsis (36.9%). The stoma was reversed in nine patients after a mean follow‐up of 35.8 months. Risk factors associated with a permanent stoma were perianal sepsis (p = 0.010), interruptions during radiotherapy for more than 7 days (p = 0.010), male sex (p = 0.013), poor performance status (Eastern Cooperative Oncology Group [ECOG] ≥ 2) (p = 0.023), large tumors (p = 0.045), and cisplatin‐based chemotherapy (p = 0.047).Conclusions: Pretreatment stomas are unlikely to be reversed, and risk factors for a permanent stoma are perianal sepsis, interruptions during radiotherapy for more than 7 days, male sex, poor performance status (ECOG ≥ 2), large tumors, and cisplatin‐based chemotherapy.Keywords
This publication has 29 references indexed in Scilit:
- Induction Chemotherapy and Dose Intensification of the Radiation Boost in Locally Advanced Anal Canal Carcinoma: Final Analysis of the Randomized UNICANCER ACCORD 03 TrialJournal of Clinical Oncology, 2012
- Long-Term Follow-Up of a Phase II Trial of High-Dose Radiation With Concurrent 5-Fluorouracil and Cisplatin in Patients With Anal Cancer (ECOG E4292)International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- HPV Vaccine against Anal HPV Infection and Anal Intraepithelial NeoplasiaNew England Journal of Medicine, 2011
- Defunctioning stomas prior to chemoradiation for anal cancer are usually permanentColorectal Disease, 2010
- Prognostic factors derived from a prospective database dictate clinical biology of anal cancerCancer, 2010
- Stoma complications: a literature overviewColorectal Disease, 2009
- Evaluation of Planned Treatment Breaks During Radiation Therapy for Anal Cancer: Update of RTOG 92-08International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2008
- Predictors and Patterns of Recurrence After Definitive Chemoradiation for Anal CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2007
- Risk Factors Associated With Requiring a Stoma for the Management of Anal CancerDiseases of the Colon & Rectum, 2004
- Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycinThe Lancet, 1996